Los Gatos, CA, United States of America

Saira Singh

This inventor holds 1 USPTO granted patent. Top assignee: Matrix Pharmaceutical, Inc.. Active years: 1999.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Saira Singh

Introduction

Saira Singh is a notable inventor based in Los Gatos, California. She has made significant contributions to the field of medicine, particularly in the treatment of cellular proliferative diseases. Her innovative approach combines chemotherapeutic agents with cell membrane permeants to enhance treatment efficacy.

Latest Patents

Saira Singh holds 1 patent for her invention titled "Use of cell membrane permeants in the treatment of cellular." This patent outlines methods for treating hosts suffering from cellular proliferative diseases through the administration of a chemotherapeutic agent alongside a cell membrane permeant. The methods described in her patent aim to improve the efficacy of the chemotherapeutic agent while reducing toxicity to the host.

Career Highlights

Saira Singh is currently employed at Matrix Pharmaceutical, Inc., where she continues to develop her innovative ideas. Her work focuses on enhancing cancer treatment methodologies, which have the potential to significantly impact patient outcomes.

Collaborations

Saira has collaborated with esteemed colleagues, including Richard E. Jones and Dennis M. Brown. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in their respective fields.

Conclusion

Saira Singh's contributions to medical innovation exemplify the impact of combining scientific research with practical applications. Her work continues to pave the way for advancements in cancer treatment, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…